These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22732476)

  • 41. 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
    Blum KA; Bartlett NL
    Expert Opin Biol Ther; 2004 Aug; 4(8):1323-31. PubMed ID: 15268665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined treatment of pancreatic cancer xenograft with
    Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T; Higashi T
    World J Gastroenterol; 2017 Nov; 23(42):7551-7562. PubMed ID: 29204055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody.
    Vallera DA; Elson M; Brechbiel MW; Dusenbery KE; Burns LJ; Jaszcz WB; Ramsay NK; Panoskaltsis-Mortar A; Kuroki DW; Wagner JE; Vitetta ES; Kersey JH
    Cancer Biother Radiopharm; 2004 Feb; 19(1):11-23. PubMed ID: 15068607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct measurement of intratumor dose-rate distributions in experimental xenografts treated with 90Y-labeled radioimmunotherapy.
    Mayer R; Dillehay LE; Shao Y; Zhang YG; Song S; Bartholomew RM; Mackenson DG; Williams JR
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):147-57. PubMed ID: 7721611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. (177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.
    Beckford Vera DR; Eigner S; Eigner Henke K; Leyva Montaña R; Melichar F; Beran M
    Recent Results Cancer Res; 2013; 194():301-17. PubMed ID: 22918766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
    Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
    Masters GR; Berger MA; Albone EF
    Gynecol Oncol; 2006 Sep; 102(3):462-7. PubMed ID: 16434088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.
    Zhang M; Yao Z; Garmestani K; Yu S; Goldman CK; Paik CH; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Biother Radiopharm; 2009 Jun; 24(3):303-9. PubMed ID: 19538052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
    Schneider DW; Heitner T; Alicke B; Light DR; McLean K; Satozawa N; Parry G; Yoo J; Lewis JS; Parry R
    J Nucl Med; 2009 Mar; 50(3):435-43. PubMed ID: 19223400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intralesional radiolabeled human monoclonal IgM in human tumor xenografts.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    Radiother Oncol; 1997 Sep; 44(3):283-93. PubMed ID: 9380829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extracellular matrix remodeling in vivo for enhancing tumor-targeting efficiency of nanoparticle drug carriers using the pulsed high intensity focused ultrasound.
    Lee S; Han H; Koo H; Na JH; Yoon HY; Lee KE; Lee H; Kim H; Kwon IC; Kim K
    J Control Release; 2017 Oct; 263():68-78. PubMed ID: 28257990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pretargeted radioimmunotherapy (PRIT) using an antibody-streptavidin fusion protein in non-Hodgkin's lymphoma.
    Weiden PL
    Leuk Lymphoma; 2002 Oct; 43(10):1971-3. PubMed ID: 12481894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
    Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
    Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.
    Rudnick SI; Lou J; Shaller CC; Tang Y; Klein-Szanto AJ; Weiner LM; Marks JD; Adams GP
    Cancer Res; 2011 Mar; 71(6):2250-9. PubMed ID: 21406401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R; Chen S; Haim S; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radioimmunotherapy with 90Y-labeled monoclonal antibodies in a nude mouse ovarian cancer model.
    Kairemo K; Ljunggren K; Strand SE; Hiltunen J; Penttilä P; Nikula T; Laine A; Wahlström T
    Acta Oncol; 1993; 32(7-8):801-5. PubMed ID: 8305229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.